Dr. Puneky is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2500 North State Street
Department of Medicinedivision of Oncology
Jackson, MS 39216Phone+1 601-984-5590Fax+1 601-984-5599
Education & Training
- University of Alabama Medical CenterFellowship, Hematology and Medical Oncology, 1990 - 1991
- University of Mississippi Medical CenterFellowship, Hematology and Medical Oncology, 1988 - 1990
- University of Mississippi Medical CenterResidency, Internal Medicine, 1985 - 1988
- Louisiana State University School of Medicine in New OrleansClass of 1985
Certifications & Licensure
- MS State Medical License 1986 - 2025
- LA State Medical License 1985 - 2000
- AL State Medical License 1990 - 1994
- American Board of Internal Medicine Internal Medicine
Clinical Trials
- Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor Start of enrollment: 2007 Dec 01
- Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide Start of enrollment: 2008 Mar 01
- S0713: Oxaliplatin, Capecitabine, Cetuximab, and RT Followed By Surgery in Pts W/Stage II or III Rectal Cancer Start of enrollment: 2009 Feb 01
- Join now to see all
Publications & Presentations
PubMed
- 47 citationsChemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.Tate Thigpen, Ralph B. Vance, Louis V. Puneky, Tawfiq Khansur
Gynecologic Oncology. 1994-12-01 - 26 citationsA phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the Gynecolog...David Miller, John A. Blessing, Richard D. Drake, Robert V. Higgins, D. Scott McMeekin
Gynecologic Oncology. 2009-12-01 - 22 citationsA Phase II evaluation of weekly topotecan as a single agent second line therapy in persistent or recurrent carcinoma of the cervix: a Gynecologic Oncology Group study.James Fiorica, John A. Blessing, Louis V. Puneky, Angeles Alvarez Secord, James S. Hoffman
Gynecologic Oncology. 2009-11-01
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: